Exploring ketamine's reinforcement, cue-induced reinstatement, and nucleus accumbens cFos activation in male and female long evans rats.
Devin P Hagarty, Adam Dawoud, Alfonso Brea Guerrero, Kaynas Phillips, Caroline E Strong, Sarah Dollie Jennings, Michelle Crawford, Katherine Martinez, Olivia Csernecky, Samantha K Saland, Mohamed Kabbaj
Neuropharmacology September 1, 2024 DOI: 10.1016/j.neuropharm.2024.110008 via PubMed
Summary
AI-generated from the abstractKetamine, used for treatment-resistant depression, shows reinforcing effects in both male and female rats at higher doses (0.25 and 0.5 mg/kg/infusion), with females self-administering more at the highest dose. All doses that supported self-administration led to cue-induced reinstatement. After reinstatement, ketamine-treated animals had higher cFos protein expression in the nucleus accumbens than saline controls, with greater expression in the core than shell subregion, and no sex differences in this neural activation. These dose- and sex-dependent effects highlight the need for further research into ketamine's addictive potential, especially at lower clinical doses.
Study at a glance
| Characteristics | Preclinical experimental study Peer reviewed |
|---|---|
| Population | Long Evans rats |
| Intervention | Ketamine |
| Dose | 0, 0.125, 0.25, 0.5 mg/kg/infusion |
| Topics | Addiction |
| Keywords | Dose-response Sex differences Cfos Addiction-risk Sex-differences-behavior |
| Citations | 6 |
| Key finding | Ketamine has reinforcing effects in both sexes at higher doses, with females showing higher self-administration at the highest dose, and all doses led to cue-induced reinstatement with increased cFos expression in the nucleus accumbens core. |
Abstract
Ketamine (KET), a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist, has rapid onset of antidepressant effects in Treatment-Resistant Depression patients and repeated infusions are required to sustain its antidepressant properties. However, KET is an addictive drug, and so more preclinical and clinical research is needed to assess the safety of recurring treatments in both sexes. Thus, the aim of this study was to investigate the reinforcing properties of various doses of KET (0-, 0.125-, 0.25-, 0.5 mg/kg/infusion) and assess KET's cue-induced reinstatement and neuronal activation in both sexes of Long Evans rats. Neuronal activation was assessed using the protein expression of the immediate early gene cFos in the nucleus accumbens (Nac), an important brain area implicated in reward, reinforcement and reinstatement to most drug-related cues. Our findings show that KET has reinforcing effects in both male and female rats, albeit exclusively at the highest two doses (0.25 and 0.5 mg/kg/infusion). Furthermore, we noted sex differences, particularly at the highest dose of ketamine, with female rats displaying a higher rate of self-administration. Interestingly, all groups that self-administered KET reinstated to drug-cues. Following drug cue-induced reinstatement test in rats exposed to KET (0.25 mg/kg/infusion) or saline, there was higher cFos protein expression in KET-treated animals compared to saline controls, and higher cFos expression in the core compared to the shell subregions of the Nac. As for reinstatement, there were no notable sex differences reported for cFos expression in the Nac. These findings reveal some sex and dose dependent effects in KET's reinforcing properties and that KET at all doses induced similar reinstatement in both sexes. This study also demonstrated that cues associated with ketamine induce comparable neuronal activation in the Nac of both male and female rats. This work warrants further research into the potential addictive properties of KET, especially when administered at lower doses which are now being used in the clinic for treating various psychopathologies.